Björg Jónsdóttir1, Marta Lomnytska2,3,4, Inger Sundström Poromaa2, Ilvars Silins2, Karin Stålberg2. 1. Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. bjorjon@gmail.com. 2. Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. 3. Department of Obstetrics and Gynecology, Uppsala University Hospital, Uppsala, Sweden. 4. Institute of Oncology and Pathology, Karolinska Institutet, Karolinska, Stockholm, Sweden.
Abstract
BACKGROUND: Extent of tumor load is an important factor in the selection of ovarian cancer patients for cytoreductive surgery (CRS). The Peritoneal Cancer Index (PCI) gives exact information on tumor load but still is not standard in ovarian cancer surgery. The aim of this study was to find a PCI cutoff for incomplete CRS. The secondary aims were to identify reasons for open-close surgery and to compare surgical complications in relation to tumor burden. METHODS: The study included 167 women with stage III or IV ovarian cancer scheduled for CRS. Possible predictors of incomplete surgery were evaluated with receiver operator curves, and a PCI cutoff was identified. Surgical complications were analyzed by one-way analysis of variance and Chi square tests. RESULTS: The median PCI score for all the patients was 22 (range 3-37) but 33 (range 25-37) for the patients with incomplete surgery (n = 19). The PCI predicted incomplete CRS, with an area under the curve of 0.94 (95% confidence interval [CI], 0.91-0.98). Complete CRS was obtained for 67.2% of the patients with a PCI higher than 24, who experienced an increased rate of complications (p = 0.008). Overall major complications were found in 16.9% of the cases. Only 28.6% of the patients with a PCI higher than 33 achieved complete CRS. The reason for open-close surgery (n = 14) was massive carcinomatosis on the small bowel in all cases. CONCLUSION: The study found PCI to be an excellent predictor of incomplete CRS. Due to a lower surgical success rate, the authors suggest that neoadjuvant chemotherapy could be considered if the PCI is higher than 24. Preoperative radiologic assessment should focus on total tumor burden and not necessarily on specific regions.
BACKGROUND: Extent of tumor load is an important factor in the selection of ovarian cancerpatients for cytoreductive surgery (CRS). The Peritoneal Cancer Index (PCI) gives exact information on tumor load but still is not standard in ovarian cancer surgery. The aim of this study was to find a PCI cutoff for incomplete CRS. The secondary aims were to identify reasons for open-close surgery and to compare surgical complications in relation to tumor burden. METHODS: The study included 167 women with stage III or IV ovarian cancer scheduled for CRS. Possible predictors of incomplete surgery were evaluated with receiver operator curves, and a PCI cutoff was identified. Surgical complications were analyzed by one-way analysis of variance and Chi square tests. RESULTS: The median PCI score for all the patients was 22 (range 3-37) but 33 (range 25-37) for the patients with incomplete surgery (n = 19). The PCI predicted incomplete CRS, with an area under the curve of 0.94 (95% confidence interval [CI], 0.91-0.98). Complete CRS was obtained for 67.2% of the patients with a PCI higher than 24, who experienced an increased rate of complications (p = 0.008). Overall major complications were found in 16.9% of the cases. Only 28.6% of the patients with a PCI higher than 33 achieved complete CRS. The reason for open-close surgery (n = 14) was massive carcinomatosis on the small bowel in all cases. CONCLUSION: The study found PCI to be an excellent predictor of incomplete CRS. Due to a lower surgical success rate, the authors suggest that neoadjuvant chemotherapy could be considered if the PCI is higher than 24. Preoperative radiologic assessment should focus on total tumor burden and not necessarily on specific regions.
Authors: Anna Fagotti; Gabriella Ferrandina; Francesco Fanfani; Alfredo Ercoli; Domenica Lorusso; Marco Rossi; Giovanni Scambia Journal: Ann Surg Oncol Date: 2006-06-21 Impact factor: 5.344
Authors: J Esquivel; T C Chua; A Stojadinovic; J Torres Melero; E A Levine; M Gutman; R Howard; P Piso; A Nissan; A Gomez-Portilla; L Gonzalez-Bayon; S Gonzalez-Moreno; P Shen; J H Stewart; P H Sugarbaker; R M Barone; R Hoefer; D L Morris; A Sardi; R P Sticca Journal: J Surg Oncol Date: 2010-11-01 Impact factor: 3.454
Authors: G Passot; F Dumont; D Goéré; C Arvieux; P Rousset; J-M Regimbeau; D Elias; L Villeneuve; O Glehen Journal: Br J Surg Date: 2018-03-26 Impact factor: 6.939
Authors: A-A K Tentes; G Tripsiannis; S K Markakidis; C N Karanikiotis; G Tzegas; G Georgiadis; K Avgidou Journal: Eur J Surg Oncol Date: 2003-02 Impact factor: 4.424
Authors: Christina Fotopoulou; Benjamin P Jones; Konstantinos Savvatis; Jeremy Campbell; Maria Kyrgiou; Alan Farthing; Stephen Brett; Rene Roux; Marcia Hall; Gordon Rustin; Hani Gabra; Long Jiao; Richard Stümpfle Journal: Arch Gynecol Obstet Date: 2016-04-04 Impact factor: 2.344